🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06566053
Enrolling by invitation Observational

Establishment of a Predictive System for Perioperative Risk Assessment and Electronic Flowcharting Response Strategies in Thoracic Surgery

NCT06566053 · tracked via the Priya Life Science China tracker
Sponsor
Hengxing Liang
Phase
Observational
Started
2023-07-01
Last updated
2024-08-22

Condition(s) studied

Perioperative Complications

Investigational drug(s) / intervention(s)

Observation

Observation: Observation

Study summary

1. To establish a risk assessment scale for thoracic surgery for the Chinese population, and to classify patients; risk according to the relevant scale;
2. Combining the guidelines for the management of acute and critical illnesses in thoracic surgical care units and the characteristics of diagnosis and treatment operations, to make an AI-assisted diagnosis and treatment process software;
3. Evaluate whether the software can provide timely and correct diagnosis and treatment recommendations for critically ill patients, shorten the time for homogenized training of specialist intensivists, and reduce the hospitalization cost of patients under the review of resident training instructors of various specialties.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University for surgical treatment. Exclusion Criteria: * Patients admitted to the Department of Thoracic Surgery of the Second Xiangya Hospital of Central South University without surgical treatment. Patients under the age of 18.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
the Second Xiangya Hospital of Central South University Changsha Hunan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06566053 on ClinicalTrials.gov ↗ ← All trials in China